The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

Parents in Kerala concerned about changes in 'Mittayi' scheme for children with Type 1 diabetes, facing insulin issues.

Kirsty, Biocon's rapid-acting insulin, is the first FDA-approved interchangeable biosimilar to NovoLog in the US and will be available via prefilled pens and vials ...

The US Food and Drug Administration approved, the first rapid-acting interchangeable biosimilar product, Kirsty (insulin aspart-xjhz, as a 3 mL single-patient-use prefilled pen and 10 mL multiple-dose ...

KIRSTY is a rapid-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...

BRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, July 15, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL) , a fully int ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon announced that US FDA has approved Kirsty (insulin aspart-xjhz), 100 units/mL as the first and only ...

Biocon announced that its subsidiary, Biocon Biologics, has received US Food and Drug Administration (USFDA) approval for Kirsty (Insulin Aspart-xjhz) 100 units/ml, to improve glycemic control in ...